Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.
- Sep 2, 2021
- Fujifilm launches FUJINON Lens XF23mmF1.4 R LM WR
- Sep 2, 2021
- Fujifilm launches FUJINON Lens XF33mmF1.4 R LM WR
- Sep 2, 2021
- Fujifilm unveils the latest development roadmap for interchangeable lenses for the X Series of mirrorless digital cameras
- Sep 2, 2021
- Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream
- Aug 31, 2021
- Launch of Therapeutic Radiopharmaceutical Product, Lutathera® Injection targeting neuroendocrine tumors in Japan (FUJIFILM Toyama Chemical)
- Jul 6, 2021
- FUJIFILM Holdings adopts a “DX Vision” (FUJIFILM Holdings)
- Jun 29, 2021
- $850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity
- Jun 23, 2021
-
Marketing Authorization Granted for Lutathera® Injection in Japan
- The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors (FUJIFILM Toyama Chemical) - May 27, 2021
- FUJIFILM Wako Pure Chemical launches “E484Q mutation detection kit” reagent for detecting a SARS-CoV-2 mutation (FUJIFILM Wako Pure Chemical)
- May 18, 2021
- BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
- May 17, 2021
- FUJIFILM Wako Pure Chemical launches mutation detection kit for SARS-CoV-2 “L452R” (FUJIFILM Wako Pure Chemical)
- Apr 27, 2021
- Fujifilm sets its highest record with 23 products winning the internationally prestigious “iF Design Award”